Articlenpj biomedical innovations2026
Developing a protocol to counteract spontaneous in vitro activation of intestinal fibroblasts using design of experiments.
Article in npj biomedical innovations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In vitro studies of intestinal fibrosis are confounded by spontaneous fibroblast activation on tissue culture polystyrene, hindering the investigation of early events that initiate fibrosis. Here, we present a statistically optimized culture protocol that suppresses fibroblast activation while preserving cell viability under standard culture conditions. Using a design of experiments (DOE) framework, we systematically evaluated combinations of extracellular matrix proteins and soluble factors to identify conditions that reduce myofibroblastic marker expression and extracellular matrix production. Fibroblasts cultured under optimized conditions remained spindle-shaped, exhibited low myofibroblastic marker expression, and showed reduced collagen and fibronectin secretion without evidence of cytotoxicity. The protocol was further validated in primary human colonic fibroblasts from both male and female donors, yielding consistent suppression of activation markers with high viability. This accessible and scalable approach provides a reproducible baseline for studying fibroblast activation and supports the use of DOE as a powerful strategy for defining microenvironmental conditions that regulate fibroblast behavior in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.